Cogent Biosciences Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Andy Robbins
Chief Executive Officer (CEO)
US$7.9m
Compensación total
| Porcentaje del salario del CEO | 8.3% |
| Permanencia del CEO | 4.1yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04
Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$242m |
| Jun 30 2024 | n/a | n/a | -US$227m |
| Mar 31 2024 | n/a | n/a | -US$212m |
| Dec 31 2023 | US$8m | US$656k | -US$192m |
| Sep 30 2023 | n/a | n/a | -US$178m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$4m | US$624k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$126m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$3m | US$593k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$163m |
| Jun 30 2021 | n/a | n/a | -US$194m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$18m | US$102k | -US$179m |
Compensación vs. Mercado: La compensación total de Andy($USD7.90M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.15M).
Compensación vs. Ingresos: La compensación de Andy ha aumentado mientras la empresa no es rentable.
CEO
Andy Robbins (48 yo)
4.1yrs
Permanencia
US$7,898,772
Compensación
Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.1yrs | US$7.90m | sin datos | |
| Chief Scientific Officer | 3.6yrs | US$2.98m | 0% $ 0 | |
| Chief Medical Officer | 5.4yrs | US$3.00m | 0.0012% $ 11.9k | |
| CFO & Principal Accounting Officer | 4.3yrs | US$2.14m | sin datos | |
| Chief Technology Officer | 4yrs | sin datos | sin datos | |
| Senior Director of Investor Relations | no data | sin datos | sin datos | |
| Chief Legal Officer & Corporate Secretary | 3.5yrs | sin datos | sin datos | |
| Chief People Officer | no data | sin datos | sin datos | |
| Senior VP of Medical Affairs & Chief Patient Officer | no data | sin datos | sin datos | |
| Senior Vice President of Chemistry | no data | sin datos | sin datos | |
| VP & Head of Clinical Development | 2yrs | sin datos | sin datos | |
| Senior VP and Head of Regulatory & Pharmacovigilance | less than a year | sin datos | sin datos |
3.8yrs
Permanencia media
48yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de COGT se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.1yrs | US$7.90m | sin datos | |
| Independent Director | 5.3yrs | US$345.49k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$336.69k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$345.80k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.8yrs | US$340.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.3yrs | US$341.36k | 0% $ 0 | |
| Independent Chairman of the Board | 4.3yrs | US$364.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos |
4.3yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de COGT se considera experimentada (4.3 años de antigüedad promedio).